UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number : 001-36187

EVOGENE LTD.

(Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

~~Evogene~~On Ltd. (the “Registrant” or the “Company”) hereby announces that the shareholders of the Company approved all the proposals brought before the annual general meeting of shareholders held on August 1819, 2025, ~~(following~~Evogene aLtd. ~~one-week adjournment from the original meeting date)~~ (~~the~~ “~~Meeting~~Evogene”), ~~by the~~announced ~~respective~~ its ~~requisite~~financial ~~majority~~results infor ~~accordance~~the ~~with~~second ~~the~~quarter ~~Israeli~~ended ~~Companies~~June ~~Law~~30, ~~5759-1999,~~2025. A ~~and~~Copy ~~the Company’s articles~~ of ~~association,~~the aspress ~~described~~release inannouncing ~~the Proxy~~those ~~Statement~~results ~~which~~is ~~was~~furnished ~~attached~~ as Exhibit 99.21 to ~~the~~this ~~Company’s~~ Report of Foreign Private Issuer on Form 6-K~~, furnished to the Securities and Exchange Commission~~ (this “~~SEC~~Form 6-K”), ~~on June 17, 2025,~~ and ~~sent~~is inincorporated ~~connection~~herein ~~with~~by ~~the Meeting~~reference.

~~The~~Evogene ~~contents~~is ofholding ~~this~~a ~~Report~~conference ofcall ~~Foreign~~on ~~Private~~August ~~Issuer~~19, on2025 ~~Form~~to ~~6-K~~discuss ~~(this~~its ~~“Form~~quarterly ~~6-K”)~~results isfor ~~incorporated~~the byquarter ~~reference~~ended inJune 30, ~~the~~2025 ~~registration~~and, ~~statements~~in onconnection ~~Form~~with ~~F-3~~that ~~(SEC~~call, ~~File~~will ~~No. 333-277565),~~make ~~and~~available ~~Form~~to ~~S-8~~its ~~(File~~investors ~~Nos.~~a ~~333-193788,~~slide ~~333-201443,~~presentation ~~333-203856,~~to ~~333-259215~~provide ~~and~~additional ~~333-286197)~~information ofregarding ~~the~~its ~~Company,~~business and ~~will~~its befinancial aresults. ~~part~~That ~~thereof~~slide ~~from~~presentation ~~the~~is ~~date on~~attached ~~which~~as Exhibit 99.2 to this Form 6-K and is ~~submitted,~~incorporated toherein ~~the extent not superseded~~ by ~~documents or reports subsequently filed or furnished~~reference.

The GAAP financial statements tables contained in the press release attached to this Form 6-K are incorporated by reference in the registration statements on Form F-3 (Securities and Exchange Commission (“SEC”) File No. 333-277565), and Form S-8 (SEC File Nos. 333-259215, 333-193788, 333-201443, 333-203856, 333-286197 and 333-286197) of Evogene, and will be a part thereof from the date on which this Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: August 1819, 2025 EVOGENE LTD. (Registrant) By: /s/ Yaron Eldad ~~——————————————~~ Yaron Eldad Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release: Evogene Reports Second Quarter 2025 Financial Results.
99.2	Slide presentation for conference call of Evogene held on August 19, 2025, discussing Evogene’s quarterly financial results for the second quarter of 2025.

Filing Compare · Evogene Ltd.